80 FR 81554 - National Institute on Aging; Notice of Closed Meeting
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health Federal Register Volume 80, Issue 250 (December 30, 2015)
National Institutes of Health
Federal Register Volume 80, Issue 250 (December 30, 2015)
| Page Range | 81554-81554 | |
| FR Document | 2015-32772 |
[Federal Register Volume 80, Number 250 (Wednesday, December 30, 2015)] [Notices] [Page 81554] From the Federal Register Online [www.thefederalregister.org] [FR Doc No: 2015-32772] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute on Aging; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute on Aging Special Emphasis Panel; Rodent Tissue Bank. Date: January 29, 2016. Time: 12:30 p.m. to 2:00 p.m. Agenda: To review and evaluate contract proposals. Place: National Institute on Aging, Gateway Building, Suite 2C212, 7201 Wisconsin Avenue, Bethesda, MD 20892 (Telephone Conference Call). Contact Person: Kimberly Firth, Ph.D., National Institutes of Health, National Institute on Aging, Gateway Building, 7201 Wisconsin Avenue, Suite 2C212, Bethesda, MD 20892, 301-402-7702 firthkm@mail.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.866, Aging Research, National Institutes of Health, HHS) Dated: December 23, 2015. Melanie J. Gray, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2015-32772 Filed 12-29-15; 8:45 am] BILLING CODE 4140-01-P
![81554 Federal Register / Vol. 80, No. 250 / Wednesday, December 30, 2015 / Notices
Center Drive, Mail Stop 9702, Rockville, In Vitro/Discovery Date: January 29, 2016.
MD 20850–9702, Tel. 240–276–5515 or Time: 12:30 p.m. to 2:00 p.m.
Inventor(s): Agenda: To review and evaluate contract
email ncitechtransfer@mail.nih.gov. Nigel H. Greig (NIA), Weiming Luo proposals.
FOR FURTHER INFORMATION CONTACT: (NIA), David Tweedie (NIA), William Place: National Institute on Aging,
Information on licensing and co- Douglas Figg, Sr. (NCI), Neil Vargesson Gateway Building, Suite 2C212, 7201
development research collaborations, (Univ. Aberdeen, Scotland), and Wisconsin Avenue, Bethesda, MD 20892
and copies of the U.S. patent Shaunna Beedie (NCI & Univ. Aberdeen, (Telephone Conference Call).
applications listed below, may be Scotland) Contact Person: Kimberly Firth, Ph.D.,
Intellectual Property: National Institutes of Health, National
obtained by contacting: Attn. Invention
Institute on Aging, Gateway Building, 7201
Development and Marketing Unit, HHS Reference No. E–208–2015/0–US– Wisconsin Avenue, Suite 2C212, Bethesda,
Technology Transfer Center, National 01 MD 20892, 301–402–7702 firthkm@
Cancer Institute, 9609 Medical Center mail.nih.gov.
Drive, Mail Stop 9702, Rockville, MD U.S. Provisional Patent Application
(Catalogue of Federal Domestic Assistance
20850–9702, Tel. 240–276–5515 or No. 62/235, 105, filed September 30, Program Nos. 93.866, Aging Research,
email ncitechtransfer@mail.nih.gov. A 2015, entitled ‘‘Thalidomide/ National Institutes of Health, HHS)
signed Confidential Disclosure lenolidomide/pomalidomide analogs
that inhibit inflammation, angiogenesis’’ Dated: December 23, 2015.
Agreement may be required to receive Melanie J. Gray,
Licensing and Collaborative/Co-
copies of the patent applications. Program Analyst, Office of Federal Advisory
Development Research Opportunity:
SUPPLEMENTARY INFORMATION: The National Institute on Aging seeks Committee Policy.
Title of invention: Thalidomide/ collaborators to license or co-develop [FR Doc. 2015–32772 Filed 12–29–15; 8:45 am]
lenolidomide/pomalidomide analogs novel thalidomide analogs that BILLING CODE 4140–01–P
that inhibit inflammation, angiogenesis. demonstrate clinical potential without
Description of Technology: being teratogenic.
Thalidomide and its close analogs Contact Information: Requests for DEPARTMENT OF HEALTH AND
(lenalidomide and pomalidomide) are copies of the patent application or HUMAN SERVICES
widely used to treat a variety of inquiries about licensing and/or
diseases, such as multiple myeloma and research collaboration and co- National Institutes of Health
other cancers, as well as the symptoms development opportunities should be
of several inflammatory disorders. Office of the Director; Amended Notice
sent to John D. Hewes, Ph.D., email:
However, thalidomide is known for its of Meeting
john.hewes@nih.gov.
teratogenic adverse effects when first CFR Citation: 35 U.S.C. 209 and 37 Notice is hereby given of a correction
introduced clinically in the 1950s, and CFR part 404 in the meeting notice of the Big Data to
is associated with drowsiness and Dated: December 22, 2015. Knowledge Multi-Council Working
peripheral neuropathy. Hence, there is Thomas M. Stackhouse, Group (BD2K) that was published in the
intense interest to synthesize, identify Federal Register on Friday, December
Associate Director, Technology Transfer
and develop safer analogs. Researchers Center, National Cancer Institute. 11, 2015, 80 FRN 76996.
at the National Institute on Aging’s Drug The date of the meeting is January 11,
[FR Doc. 2015–32877 Filed 12–29–15; 8:45 am]
Design and Development Section 2016. The time and meeting access
BILLING CODE 4140–01–P
synthesized novel thalidomide analogs codes remain the same.
that demonstrate clinical potential A portion of the meeting is open to
without being teratogenic, as initially DEPARTMENT OF HEALTH AND the public, 11 a.m. to 12:00 p.m. and is
evaluated in in vivo zebrafish and HUMAN SERVICES being held by teleconference only. No
chicken embryo model systems and in physical meeting location is provided
cell culture. These new compounds National Institutes of Health for any interested individuals to listen
differentially provide potent anti- to committee discussions. Any
angiogenesis and/or anti-inflammatory National Institute on Aging; Notice of individual interested in listening to the
action. The agents have potential for Closed Meeting meeting discussions must call: 1–866–
development of new cancer therapies 692–3158 and use Passcode 2956317 for
and treatment of a number of Pursuant to section 10(d) of the access to the meeting.
neurological and systemic disorders Federal Advisory Committee Act, as
Dated: December 23, 2015.
involving chronic inflammation and amended (5 U.S.C. App.), notice is
hereby given of the following meeting. Anna Snouffer,
elevated TNF-alpha levels. Deputy Director, Office of Federal Advisory
The meeting will be closed to the
Potential Commercial Applications: Committee Policy.
public in accordance with the
—Cancer therapeutics provisions set forth in sections [FR Doc. 2015–32768 Filed 12–29–15; 8:45 am]
—Inflammatory disorders such as 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., BILLING CODE 4140–01–P
Crohn’s disease, sarcoidosis, graft- as amended. The contract proposals and
versus-host disease, and rheumatoid the discussions could disclose
arthritis confidential trade secrets or commercial DEPARTMENT OF HEALTH AND
—Neuroinflammatory disorders (acute: property such as patentable material, HUMAN SERVICES
Traumatic brain injury and stroke;
mstockstill on DSK4VPTVN1PROD with NOTICES
and personal information concerning
chronic: Parkinson’s disease, National Institutes of Health
individuals associated with the contract
Alzheimer’s disease, multiple proposals, the disclosure of which National Institute of Biomedical
sclerosis) would constitute a clearly unwarranted Imaging and Bioengineering; Notice of
Value Proposition: invasion of personal privacy. Closed Meeting
—Non-teratogenic Name of Committee: National Institute on
—Potent Aging Special Emphasis Panel; Rodent Pursuant to section 10(d) of the
Development Stage: Tissue Bank. Federal Advisory Committee Act, as
VerDate Sep<11>2014 17:59 Dec 29, 2015 Jkt 238001 PO 00000 Frm 00048 Fmt 4703 Sfmt 4703 E:\FR\FM\30DEN1.SGM 30DEN1](https://thefederalregister.org/doc/80_FR_81804/page/1.svg)
Document Created: 2015-12-30 03:15:48
Document Modified: 2015-12-30 03:15:48
| Category | Regulatory Information | |
| Collection | Federal Register | |
| sudoc Class | AE 2.7: GS 4.107: AE 2.106: | |
| Publisher | Office of the Federal Register, National Archives and Records Administration | |
| Section | Notices | |
| Dates | January 29, 2016. | |
| FR Citation | 80 FR 81554 |
2024 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR